Peter Welford
Stock Analyst at Jefferies
(0.21)
# 2207
Out of 5,253 analysts
20
Total ratings
66.67%
Success rate
7.42%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
GSK | Downgrades: Hold | n/a | n/a | n/a | 3 | Nov 12, 2024 | |
Novartis | Downgrades: Hold | n/a | n/a | n/a | 2 | Sep 3, 2024 | |
AstraZeneca | Downgrades: Hold | n/a | n/a | n/a | 4 | Jan 3, 2024 | |
Galapagos | Upgrades: Hold | 49 48 | 23.7 | 99.16% | 3 | Jan 23, 2023 | |
Genmab | Downgrades: Hold | n/a | n/a | n/a | 1 | Sep 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 28 | n/a | n/a | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | n/a | n/a | n/a | 6 | Feb 1, 2019 |